Stay updated with breaking news from Phase 2b. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
New phase 2b data from the FRONTIER 1 study showed promise for what could become the first and only oral IL-23 antagonist peptide for psoriasis.
They're extending life expectancy. >> it's what, 14 to 16 months for traditional treatment for glioblastoma. >> that's right. >> now you're giving them 28 months, maybe 30 months. what is it like to give someone that extra time? >> this is a very exciting thing for me. >> yeah. and the doctor there for 25 years has given people grim news. now he's telling them they could have extra time, andrea, to perhaps attend a wedding, go to a graduation, maybe see a grandchild. those are big life events and they mean everything for people who have this dead. >> absolutely. the vaccine is far from full ap...
The study achieved the primary endpoint of reduction in nodule hardness at 12 months and secondary endpoint of reduction in nodule size at multiple time...
STOCKHOLM, SWEDEN 1 June 2021. Karolinska Development AB (Nasdaq Stockholm: KDEV) announces today that the portfolio company Dilafor has concluded a phase 2b study with its drug candidate tafoxiparin which showed a significant positive impact on cervical ripening in first-time mothers receiving treatment to induce labor. Further and full analysis of data will be done by the company. Market analyses show that a drug that can induce cervical ripening has the potential to reach annual sales in excess of USD 1 billion in the US market alone. Karolinska Development will obtain an external assessmen...
CONWAY — Memorial Hospital announced it is opening up more appointments for Phase 1B of COVID-19 vaccinations and says that people can now schedule those appointments directly on the hospital’s